CA2436076A1 - Methodes et compositions permettant de stimuler l'angiogenese - Google Patents
Methodes et compositions permettant de stimuler l'angiogenese Download PDFInfo
- Publication number
- CA2436076A1 CA2436076A1 CA002436076A CA2436076A CA2436076A1 CA 2436076 A1 CA2436076 A1 CA 2436076A1 CA 002436076 A CA002436076 A CA 002436076A CA 2436076 A CA2436076 A CA 2436076A CA 2436076 A1 CA2436076 A1 CA 2436076A1
- Authority
- CA
- Canada
- Prior art keywords
- pdgf
- vegf
- fgf
- angiogenesis
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title claims abstract description 20
- 108010081589 Becaplermin Proteins 0.000 title claims description 115
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000006444 vascular growth Effects 0.000 claims abstract description 8
- 239000003094 microcapsule Substances 0.000 claims description 61
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 54
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 47
- 229920002684 Sepharose Polymers 0.000 claims description 39
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 37
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 35
- 229920000669 heparin Polymers 0.000 claims description 35
- 229960002897 heparin Drugs 0.000 claims description 35
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 34
- 229940072056 alginate Drugs 0.000 claims description 34
- 235000010443 alginic acid Nutrition 0.000 claims description 34
- 229920000615 alginic acid Polymers 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 24
- 239000000560 biocompatible material Substances 0.000 claims description 21
- 208000028867 ischemia Diseases 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 9
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 8
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 6
- 108010059616 Activins Proteins 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 5
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 5
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 5
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 5
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 5
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 5
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 5
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 5
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 5
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108050009450 Neuropilin Proteins 0.000 claims description 5
- 102000002111 Neuropilin Human genes 0.000 claims description 5
- 108010081689 Osteopontin Proteins 0.000 claims description 5
- 102000004264 Osteopontin Human genes 0.000 claims description 5
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 5
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 claims description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 5
- 102000005162 pleiotrophin Human genes 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 4
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 4
- 101800004490 Endothelin-1 Proteins 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- SCRCZNMJAVGGEI-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;oxepan-2-one Chemical compound O=C1COC(=O)CO1.O=C1CCCCCO1 SCRCZNMJAVGGEI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 229950010732 poliglecaprone Drugs 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 102100033902 Endothelin-1 Human genes 0.000 claims 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 3
- -1 cationic lipid Chemical class 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 39
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 108010082117 matrigel Proteins 0.000 description 28
- 230000002491 angiogenic effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- 210000004088 microvessel Anatomy 0.000 description 22
- 239000008188 pellet Substances 0.000 description 20
- 239000002775 capsule Substances 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000013613 expression plasmid Substances 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 16
- 210000003098 myoblast Anatomy 0.000 description 15
- 230000003389 potentiating effect Effects 0.000 description 11
- 102000008076 Angiogenic Proteins Human genes 0.000 description 10
- 108010074415 Angiogenic Proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003489 abdominal muscle Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 238000011179 visual inspection Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000003302 anti-idiotype Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des méthodes permettant de stimuler l'angiogenèse par l'administration de facteurs angiogéniques. Ces facteurs peuvent être administrés sous forme de gradient dans une zone de tissu localisée afin de diriger la croissance vasculaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26445701P | 2001-01-26 | 2001-01-26 | |
| US60/264,457 | 2001-01-26 | ||
| PCT/US2002/001666 WO2002058718A2 (fr) | 2001-01-26 | 2002-01-18 | Methodes et compositions permettant de stimuler l'angiogenese |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2436076A1 true CA2436076A1 (fr) | 2002-08-01 |
Family
ID=23006154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002436076A Abandoned CA2436076A1 (fr) | 2001-01-26 | 2002-01-18 | Methodes et compositions permettant de stimuler l'angiogenese |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1355659A2 (fr) |
| JP (1) | JP4434584B2 (fr) |
| AU (1) | AU2002247007B2 (fr) |
| CA (1) | CA2436076A1 (fr) |
| WO (1) | WO2002058718A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020072489A1 (en) * | 1998-10-13 | 2002-06-13 | Whitehouse Martha J. | Angiogenically effective unit dose of FGF-2 and method of use |
| JP2005168654A (ja) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | 増殖因子結合低分子ヘパリン修飾体 |
| FR2891149B1 (fr) | 2005-09-26 | 2007-11-30 | Biodex Sarl | Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes. |
| EP1948210A4 (fr) | 2005-11-08 | 2010-07-14 | Found Biomedical Res & Innov | Methode de traitement d'une maladie cardiaque ischemique |
| FR2914191A1 (fr) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | Composition angiogenique. |
| KR20110061639A (ko) * | 2008-09-26 | 2011-06-09 | 아도시아 | 폴리사카라이드 및 ｈｐｂ로 구성된 복합체 |
| WO2010078624A1 (fr) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Matériaux et méthodes pour le traitement de l’hypertension |
| GB201504665D0 (en) * | 2015-03-19 | 2015-05-06 | Cell Therapy Ltd | Composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889919A (en) * | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
| US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| NZ237832A (en) * | 1990-04-17 | 1994-05-26 | Curative Tech Inc | Coating a prosthetic surface with mammalian cells |
| CA2161669A1 (fr) * | 1993-04-29 | 1994-11-10 | Roger Khalil Khouri | Utilisation d'un facteur de croissance derive de plaquettes pour ameliorer la circulation colaterale |
| US6333194B1 (en) * | 1999-01-19 | 2001-12-25 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
-
2002
- 2002-01-18 WO PCT/US2002/001666 patent/WO2002058718A2/fr active Application Filing
- 2002-01-18 JP JP2002559052A patent/JP4434584B2/ja not_active Expired - Fee Related
- 2002-01-18 EP EP02714757A patent/EP1355659A2/fr not_active Ceased
- 2002-01-18 AU AU2002247007A patent/AU2002247007B2/en not_active Ceased
- 2002-01-18 CA CA002436076A patent/CA2436076A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002058718A3 (fr) | 2003-04-17 |
| EP1355659A2 (fr) | 2003-10-29 |
| WO2002058718A2 (fr) | 2002-08-01 |
| JP4434584B2 (ja) | 2010-03-17 |
| AU2002247007B2 (en) | 2006-12-07 |
| JP2005506279A (ja) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001268149B2 (en) | Methods and compounds for controlled release of recombinant parvovirus vectors | |
| JP4859317B2 (ja) | 薬剤放出生分解性繊維インプラント | |
| US20030139333A1 (en) | Methods and compositions for promoting angiogenesis | |
| US20080031923A1 (en) | Biologic Replacement for Fibrin Clot | |
| EA001616B1 (ru) | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре | |
| CA2433936A1 (fr) | Procede d'injection myocardiale localisee dans le traitement du myocarde ischemique | |
| WO2004030706A2 (fr) | Implants bioactifs | |
| CN1198675A (zh) | 含有hgf基因的药物 | |
| JP2004523484A (ja) | 電気処理されたコラーゲン | |
| AU2002247007B2 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
| US20080102059A1 (en) | Treatment for arthritis | |
| AU772857B2 (en) | Method of inducing angiogenesis | |
| AU2002247007A1 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
| JP2004532802A (ja) | 薬剤送達および細胞被包における電気処理 | |
| WO1989007944A1 (fr) | Procede et dispositif de neovascularisation a localisation controlee | |
| CN103638002A (zh) | 包囊的肝细胞组合物 | |
| EA019099B1 (ru) | Способ направленной доставки трансгена в миокард пациента с ишемией миокарда | |
| CN1630538A (zh) | 用vegf－b刺激血管生成 | |
| Goodrich | Gene therapy and tissue engineering | |
| ES2434257T3 (es) | Coágulos de células hematopoyéticas no poliméricos para suministro de agentes activos | |
| US20020013261A1 (en) | Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers | |
| Vranckx et al. | 15 Gene Transfer of Growth Factors for Wound Repair | |
| US20070123486A1 (en) | Composition for coordinated VEGF and PDGF expression, and methods of use | |
| Davidson | 13 Gene Therapy of Wounds | |
| Wnek et al. | Gene-Activated Matrix/Neil Davies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |